JCR Pharmaceuticals Presents Long-Term Clinical Data on Pabinafusp Alfa for the Treatment of Mucopolysaccharidosis Type II (MPS II) at ICIEM 2025

HYOGO, Japan--(BUSINESS WIRE)--JCR announced that it presented new data from its pipeline of brain-penetrant enzyme replacement therapies at the 15th ICIEM 2025. ...